Paterna BioSciences, a Salt Lake City, UT-based biotechnology company dedicated to solving male infertility, raised $6M in Seed funding.
The round was led by SpringTide Ventures, with participation from e184, the Utah Innovation Fund, Freya Ventures, Divergent Capital, Seaside Ventures, and several individual investors.
The company intends to use the funds to accelerate the development of its in vitro spermatogenesis (IVS) technology through preclinical development, as well as to develop its infrastructure, and grow its team.
Led by Alexander Pastuszak, MD, PhD, CEO, Paterna BioSciences is focused on solving male infertility through innovative approaches for in vitro spermatogenesis (IVS), a novel treatment by growing healthy sperm in a laboratory from the male’s own cells. It aims to improve human reproductive health by partnering with in vitro fertilization (IVF) clinics to enhance success rates, engaging men in optimizing their reproductive health, and expanding the treatment options for IVF.
Paterna expects to enter early-phase studies in 2025 and will bring its male fertility solution to market after FDA approval.
FinSMEs